Oxaliplatin Pharmachemie

Oxaliplatin Pharmachemie

oxaliplatin

Manufacturer:

Pharmachemie/Teva

Distributor:

Pacific Healthcare
Concise Prescribing Info
Contents
Oxaliplatin
Indications/Uses
In combination w/ 5-FU & folinic acid for adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor; treatment of metastatic CRC.
Dosage/Direction for Use
To be administered as 2-6 hr IV infusion before fluoropyrimidines. Adult Adjuvant treatment 85 mg/m2 every 2 wk for 12 cycles (6 mth). Metastatic CRC 85 mg/m2 every 2 wk.
Contraindications
Pregnancy & lactation. Peripheral sensitive neuropathy, myelosuppression, severe renal impairment.
Special Precautions
Monitor renal function in case of moderate renal impairment. History of allergic reaction to platinum compd. Avoid extravasation. Monitor neurological & haematological toxicity before therapy & then periodically. In case of acute laryngopharyngeal dysaesthesia, administer the next infusion over 6 hr. Discontinue in case of unexplained resp symptoms. Male patients should not father a child during & until 6 mth after the end of therapy. May impair ability to drive or operate machinery.
Adverse Reactions
Diarrhea, nausea, vomiting, mucositis; neutropenia, thrombocytopenia; acute & dose cumulative peripheral sensory neuropathy.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Oxaliplatin Pharmachemie infusion 100 mg/20 mL
Packing/Price
1's
Form
Oxaliplatin Pharmachemie infusion 50 mg/10 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in